Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.
Pharmaceutical Technology on MSN3d
FDA approves MSD’s KEYTRUDA as first-line MPM treatmentThe US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM) ...
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback